drugset / Trial / NCT06997081
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.
Timeline
- Start
- 2025-09-16
- Primary completion
- 2030-09-30
- Completion
- 2030-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 4 mg | Oral |
| Subject | Elranatamab | Monoclonal antibody | 76 mg | Subcutaneous |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |